An interventional study of Routine Guideline-Based Conservative Care and Clinician-Supervised, Platform-Assisted Conservative Management in Adolescent Idiopathic Scoliosis (AIS), sponsored by Hangzhou Medical College. Recruiting at 1 site in China. Open to participants aged 12 Years to 16 Years. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Hangzhou Medical College · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Scoliosis with a site in China — 22 open to participants now, 26 under way, none of them phase 3. Scoliosis · China.
Among the 55 studies in Scoliosis with a site in China, this one is the 22nd largest by planned enrollment of the 37 interventional ones that give a count, is one of 5 that started in 2025, is one of 31 with no phase, reaches primary completion later than 11 of the 25 other live ones, and was the 33rd registered.
660 studies on the registry are indexed under Scoliosis; 185 are open to participants now.
Browse Scoliosis studies →22 of the 55 studies in Scoliosis with a site in China are open now. Recruiting first, the newest first:
Peking Union Medical College Hospital · Sites in China
Ages 10–17
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 10–18
Second Affiliated Hospital of Wenzhou Medical University · Sites in China
Ages 10–15
Peking Union Medical College Hospital · Sites in China
Ages 10–18
Second Affiliated Hospital of Wenzhou Medical University · Sites in China
Ages 6–15
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 117 Scoliosis studies recruiting now, 23 (20%) set no upper age limit and 88 (75%) stop at 75 or younger; 98 take children under 18; 14 take healthy volunteers.
This study: 12 Years to 16 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 76 is above the median of 45 across 386 interventional studies indexed under Scoliosis.
Median enrollment 100 across the 37 interventional studies, 200 across the 18 observational. Of the 24 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 55 has an industry lead sponsor. The 10 most frequent:
Hangzhou Medical College is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Hangzhou Medical College has 1 study filed under Scoliosis — fewer than ten, so there is no comparison to draw.
10 of the studies in Scoliosis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06314594Hangzhou Medical CollegeProtocol for a Randomized Controlled Trial of a Clinician-Supervised Home-School-Hospital-Linked Digital Health Platform-Supported Conservative Management Pathway for AIS | 2026-11-30 |
| NCT07899294Jiawei JiangConstruction of a Screening and Precision Intervention System for Adolescent Idiopathic Scoliosis Based on the DIERS Spinal Moiré System | 2026-12 |
| NCT06470165Xuanwu Hospital, BeijingPriority-Matching Correction Technique in Degenerative Lumbar Scoliosis | 2026-12-31 |
| NCT06728046West China HospitalErector Spinae Plane Block v.s Patient Controlled Analgesia in Correction Surgery for Idiopathic Scoliosis | 2026-12-31 |
| NCT06506227The First Affiliated Hospital of Zhejiang Chinese Medical UniversityResearch on Key Technologies for Risk Prediction and Precise Diagnosis and Treatment of AIS Based on Epigene-phenotype | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 55 studies in Scoliosis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Adolescent idiopathic scoliosis (AIS) brings substantial physical and psychological burden to affected teenagers, and current conservative follow-up management is fragmented under routine clinical settings. This single-center, superiority, parallel-group, 1:1 randomized controlled trial with assessor-blinded outcome evaluation will compare a clinician-supervised, platform-supported collaborative care pathway with routine guideline-based conservative care in 76 adolescents with mild-to-moderate AIS. Participants will be assessed at baseline, 4-month (primary endpoint), 8-month, and 12-month follow-up. The primary outcome is the change in Cobb angle from baseline to 4 months. Secondary outcomes include treatment adherence, mental-health status, medical expenditure, participant and guardian satisfaction, and safety outcomes. The primary analysis will follow the intention-to-treat principle. The first participant was enrolled on 26 March 2025; to date, 35 of the target 76 participants have been recruited.
Adolescent idiopathic scoliosis (AIS) is the most prevalent form of scoliosis, affecting 2% to 4% of the global teenage population and imposing substantial physical and psychological burdens. In China, a 2024 systematic review and modelling study estimated that the prevalence of idiopathic scoliosis among children aged 5-18 years was 0.79% in 2020, corresponding to approximately 1.81 million affected children. Current conservative follow-up management for adolescents with AIS remains fragmented under routine clinical settings, with limited integration across home, school, and hospital care.
This trial evaluates the clinical effectiveness of a comprehensive digital health management platform that supports a clinician-supervised, home-school-hospital collaborative care pathway for the conservative management of adolescents with established AIS. The platform integrates nine functional modules: electronic health records, disease risk early warning, health intervention and promotion, standardized health education, follow-up management, system administration, data quality control and review, data analysis and utilization, and visual data display. It serves solely as a clinical decision-support tool; all platform-generated recommendations must be manually reviewed, adjusted, and formally approved by licensed clinicians before being shared with patients.
The trial is a single-center, superiority, parallel-group, 1:1 randomized controlled trial with assessor-blinded outcome evaluation. A total of 76 eligible adolescents with mild-to-moderate AIS (Cobb angle 10 degrees to less than 45 degrees, aged 12-16 years) will be randomly allocated to either the control group receiving routine guideline-based conservative care or the intervention group receiving clinician-supervised, platform-supported collaborative care. Both groups have access to the same guideline-based conservative treatment options, including observation, physiotherapeutic scoliosis-specific exercises (PSSE), specialized inpatient rehabilitation, and bracing, in accordance with the 2016 SOSORT guidelines. Randomization will be stratified by baseline Cobb-angle strata (10-24 degrees vs 25-44 degrees) and skeletal maturity (Risser 0-2 vs Risser 3-5).
Outcome assessments will be conducted at baseline and at 4, 8, and 12 months. The primary outcome is the change in Cobb angle from baseline to the 4-month endpoint. Secondary outcomes include treatment adherence, mental-health status (assessed with the Hamilton Depression Rating Scale-17), cumulative direct out-of-pocket medical expenditure, participant and guardian satisfaction, and safety outcomes. The primary analysis will follow the intention-to-treat principle and will use analysis of covariance adjusting for baseline Cobb angle. Sensitivity analyses include per-protocol analysis, multiple imputation under missing-at-random assumptions, complete-case analysis, and pattern-mixture-model-based analyses for missing-not-at-random scenarios.
The first participant was enrolled on 26 March 2025. To date, 35 of the target 76 participants have been recruited. No primary endpoint outcome data have been unlocked or analysed at the time of this protocol version.
The criteria were revised on the registry on Oct 27, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Control participants will receive routine clinician-directed conservative management in accordance with the 2016 SOSORT guidelines, including observation (follow-up every 3-8 months), physiotherapeutic scoliosis-specific exercises (PSSE, 2-7 sessions per week), specialized inpatient rehabilitation (SIR, a 4-week intensive program of 1 h/day, 5 days/week), and bracing (nighttime rigid bracing 8 h/day; part-time rigid bracing 15 h/day; full-time rigid bracing 20 h/day) as clinically indicated. Care is delivered through routine outpatient visits, paper-based education materials, and clinic-driven follow-up reminders via telephone or SMS. Participants in this arm have no access to the digital health management platform.
Other: Routine Guideline-Based Conservative Care
Intervention participants will receive individualized conservative management supported by the comprehensive digital health management platform and supervised by licensed clinicians. The same guideline-based treatment options as the control group are available (observation, PSSE, specialized inpatient rehabilitation, and bracing), with treatment selection rules strictly following the 2016 SOSORT guidelines. The platform generates decision-support recommendations based on clinical characteristics, radiographic findings, and lifestyle-related risk factors; all platform-generated suggestions must be manually reviewed, adjusted, and formally approved by a licensed clinician before implementation. The platform provides treatment reminders, standardized health education, follow-up scheduling, and secure cross-party communication linking participants, families, schools, and healthcare providers (home-school-hospital collaborative care model).
Behavioral: Clinician-Supervised, Platform-Assisted Conservative Management
Routine conservative management according to the 2016 SOSORT guidelines, comprising observation, physiotherapeutic scoliosis-specific exercises, specialized inpatient rehabilitation, and bracing as clinically indicated. Delivered through routine outpatient consultations; participants have no access to the digital health management platform.
Individualized conservative management supported by the comprehensive digital health management platform. The platform generates decision-support recommendations for observation, PSSE, specialized inpatient rehabilitation, or bracing, which must be reviewed, modified as needed, and formally approved by licensed clinicians before implementation. Platform functions include treatment reminders, standardized health education, follow-up scheduling, and home-school-hospital communication. The platform serves solely as a clinical decision-support tool and cannot generate automatic prescriptions or override clinical judgement.
Change in Cobb Angle
Change in Cobb angle from baseline to the 4-month endpoint (baseline Cobb angle minus 4-month Cobb angle; positive value represents curve improvement). Cobb angle will be measured on standing posteroanterior full-spine radiographs by two independent outcome assessors blinded to group allocation, following SRS measurement protocols; a third senior spine specialist arbitrates when disagreement exceeds 3 degrees. Patients wearing braces must remove the brace for at least 24 hours before radiography.
Time frame: Baseline and Month 4 (primary endpoint)
Treatment Adherence
For participants prescribed PSSE: exercise adherence = number of completed prescribed PSSE sessions / total number of prescribed sessions x 100%. For participants prescribed bracing: brace-wear adherence = actual wear-time / prescribed daily wear-time x 100%. For participants under observation-only, adherence is coded as not-applicable. Identical definitions and assessment intervals are used in both groups.
Time frame: Throughout the 4-month intervention period
Mental Health Status (Hamilton Depression Rating Scale-17)
Depression status will be assessed using the 17-item Hamilton Depression Rating Scale (HAMD-17). Trained research investigators will perform face-to-face clinician-rated interviews adapted for adolescent participants.
Time frame: Baseline, Month 4, Month 8, and Month 12
Direct Out-of-Pocket Medical Expenditure
Cumulative direct out-of-pocket medical expenses related to scoliosis management will be recorded from the family/guardian societal perspective.
Time frame: Month 4 and Month 12
Participant and Guardian Satisfaction
Participant and guardian satisfaction will be evaluated using a previously validated custom standardized satisfaction questionnaire (provided within the supplementary material).
Time frame: Month 4 and Month 12
Safety Outcomes (Adverse Events)
Adverse events and serious adverse events will be recorded and graded according to CTCAE version 5.0. Serious adverse events will be reported to the ethics committee; participants experiencing SAEs do not automatically withdraw from the trial.
Time frame: Baseline, Month 4, Month 8, and Month 12
Started Mar 2025 (actual). Primary completion is estimated for Nov 2026, 20 months after the start.
Of 224 non-industry interventional studies with no phase under Scoliosis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 58. This study's planned 20 months is close to that.
Counting every sponsor, half of 234 studies reached it within 22 months; a quarter within 8 and three quarters within 60.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: start Aug 2025 → Mar 2025 and primary completion Dec 2025 → Nov 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hangzhou Medical College